PASG logo

Passage Bio (PASG) Company Overview

Profile

Full Name:

Passage Bio, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

February 28, 2020

Indexes:

Not included

Description:

Passage Bio is a biotechnology company focused on developing gene therapies for rare genetic disorders. They aim to create innovative treatments that can improve patients' lives by addressing the underlying causes of these diseases. Their work combines advanced science with a commitment to patient care.

Events Calendar

Earnings

Next earnings date:

Mar 4, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 4, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Nov 14, 24 Chardan Capital
Buy
Nov 14, 24 Canaccord Genuity
Buy
Sep 17, 24 Canaccord Genuity
Buy
Sep 3, 24 Rodman & Renshaw
Buy
May 15, 24 Canaccord Genuity
Buy
Mar 5, 24 Canaccord Genuity
Buy
Nov 14, 23 Raymond James
Outperform
Aug 8, 23 Chardan Capital
Buy
May 12, 23 Raymond James
Outperform
Dec 15, 22 Chardan Capital
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
PASG
globenewswire.comNovember 6, 2024

PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13, 2024 at 2:30 p.m. ET.

Passage Bio Welcomes Tom Kassberg to Board of Directors
Passage Bio Welcomes Tom Kassberg to Board of Directors
Passage Bio Welcomes Tom Kassberg to Board of Directors
PASG
globenewswire.comSeptember 10, 2024

PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases.

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
PASG
globenewswire.comAugust 1, 2024

Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA Biotherapeutics, a new company co-founded by Dr. James M. Wilson

Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PASG
zacks.comJune 18, 2024

The heavy selling pressure might have exhausted for Passage Bio (PASG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy
All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy
All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy
PASG
zacks.comMay 16, 2024

Passage Bio (PASG) has been upgraded to a Zacks Rank #2 (Buy), indicating increasing confidence in the company's earnings potential. This could lead to a rise in the stock price in the short run.

Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
PASG
Zacks Investment ResearchMarch 7, 2024

Does Passage Bio, Inc. (PASG) have what it takes to be a top stock pick for momentum investors? Let's find out.

FAQ

  • What is the ticker symbol for Passage Bio?
  • Does Passage Bio pay dividends?
  • What sector is Passage Bio in?
  • What industry is Passage Bio in?
  • What country is Passage Bio based in?
  • When did Passage Bio go public?
  • Is Passage Bio in the S&P 500?
  • Is Passage Bio in the NASDAQ 100?
  • Is Passage Bio in the Dow Jones?
  • When was Passage Bio's last earnings report?
  • When does Passage Bio report earnings?
  • Should I buy Passage Bio stock now?

What is the ticker symbol for Passage Bio?

The ticker symbol for Passage Bio is NASDAQ:PASG

Does Passage Bio pay dividends?

No, Passage Bio does not pay dividends

What sector is Passage Bio in?

Passage Bio is in the Healthcare sector

What industry is Passage Bio in?

Passage Bio is in the Biotechnology industry

What country is Passage Bio based in?

Passage Bio is headquartered in United States

When did Passage Bio go public?

Passage Bio's initial public offering (IPO) was on February 28, 2020

Is Passage Bio in the S&P 500?

No, Passage Bio is not included in the S&P 500 index

Is Passage Bio in the NASDAQ 100?

No, Passage Bio is not included in the NASDAQ 100 index

Is Passage Bio in the Dow Jones?

No, Passage Bio is not included in the Dow Jones index

When was Passage Bio's last earnings report?

Passage Bio's most recent earnings report was on Nov 13, 2024

When does Passage Bio report earnings?

The next expected earnings date for Passage Bio is Mar 4, 2025

Should I buy Passage Bio stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions